Clinical trial
A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
NCT04312594 is registered in ClinicalTrials.gov with Suzhou Zelgen Biopharmaceuticals Co.,Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 8, 2020
- Completion date
- June 9, 2022
- Enrollment
- 91 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.